0 avis
MINI-FOCUS: INFLAMMATION IN CARDIAC INJURY The IL-1b Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure
Archive ouverte
Edité par CCSD -
International audience. HIGHLIGHTS Immediate IL-1b antibody gevokizumab administration reduces ischemia/ reperfusion related infarct size. Immediate and late IL-1b antibody gevokizumab administration improves heart failure related left ventricular remodeling. IL-1b antibody gevokizumab improves heart failure related coronary dysfunction. From